SSA
GRTX

Schonfeld Strategic Advisors’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-147,300
Closed -$460K – 2447
2023
Q2 		$460K Buy
147,300
+11,200
+8% +$33.3K ﹤0.01% 1253
2023
Q1 		$348K Buy
+136,100
New +$281K ﹤0.01% 1310
2022
Q2 		– Sell
-26,600
Closed -$63K – 3143
2022
Q1 		$63K Buy
+26,600
New +$69.3K ﹤0.01% 2311
2021
Q2 		– Sell
-54,488
Closed -$481K – 2407
2021
Q1 		$481K Buy
+54,488
New +$598K 0.01% 1159

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Schonfeld Strategic Advisors's GRTX Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2023, closing a stake of 147,300 shares — an estimated $460K sold.

Schonfeld Strategic Advisors first reported a position in GRTX in Q1 2021 and held it in 4 quarters. The position peaked at $481K in Q1 2021. 38 funds tracked by Wall St. Rank hold GRTX as of Q3 2023.

  • Schonfeld Strategic Advisors reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 147,300 Galera Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $460K.
  • Schonfeld Strategic Advisors first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Galera Therapeutics, Inc. Common Stock position peaked at $481K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.